Chidambaram Raghavan, MD
Internal Medicine · Powder Springs, GANPI 1326237322
Payments from drug & device makers
Across 150 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$456
- Lilly USA, LLC$329
- Novo Nordisk$323
- Astellas Pharma US Inc$238
- Paratek Pharmaceuticals, Inc.$122
- plus $611 from 12 others
What the payments were for
- Food & beverage$3,45397%
- Education$1063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 67 | $1,479 |
| Amgen | 20 | $456 |
| Lilly USA, LLC | 17 | $329 |
| Novo Nordisk | 12 | $323 |
| Astellas Pharma US Inc | 3 | $238 |
| Paratek Pharmaceuticals, Inc. | 7 | $122 |
| Mayne Pharma Commercial LLC | 1 | $122 |
| AbbVie | 2 | $120 |
| Boehringer Ingelheim | 5 | $97 |
| Pfizer | 4 | $78 |
| Exact Sciences | 3 | $46 |
| Genentech USA, Inc. | 2 | $35 |
| Abbott | 1 | $23 |
| Merck | 2 | $23 |
| GSK | 1 | $19 |
| Bausch Health US, LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$330
- Wegovy$122
- NEXTSTELLIS$122
- Veozah$116
- Orilissa$104
How this compares
$3,559 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 27 | $1,423 |
| Rosuvastatin Calcium | 58 | $784 |
| Omeprazole | 64 | $552 |
| Atorvastatin Calcium | 63 | $513 |
| Levothyroxine Sodium | 63 | $491 |
| Olmesartan Medoxomil | 45 | $425 |
| Levocetirizine Dihydrochloride | 34 | $367 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $359 |
| Metoprolol Succinate | 18 | $338 |
| Amlodipine Besylate | 56 | $278 |
| Metoprolol Tartrate | 52 | $225 |
| Gabapentin | 23 | $222 |
| Montelukast Sodium | 24 | $210 |
| Pantoprazole Sodium | 24 | $203 |
| Pravastatin Sodium | 23 | $189 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Powder Springs
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.